These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25137402)

  • 1. Is there still a role for low-dose dopamine use in acute heart failure?
    Torres-Courchoud I; Chen HH
    Curr Opin Crit Care; 2014 Oct; 20(5):467-71. PubMed ID: 25137402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure).
    Wan SH; Stevens SR; Borlaug BA; Anstrom KJ; Deswal A; Felker GM; Givertz MM; Bart BA; Tang WH; Redfield MM; Chen HH
    Circ Heart Fail; 2016 Aug; 9(8):. PubMed ID: 27512103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.
    Chen HH; Anstrom KJ; Givertz MM; Stevenson LW; Semigran MJ; Goldsmith SR; Bart BA; Bull DA; Stehlik J; LeWinter MM; Konstam MA; Huggins GS; Rouleau JL; O'Meara E; Tang WH; Starling RC; Butler J; Deswal A; Felker GM; O'Connor CM; Bonita RE; Margulies KB; Cappola TP; Ofili EO; Mann DL; Dávila-Román VG; McNulty SE; Borlaug BA; Velazquez EJ; Lee KL; Shah MR; Hernandez AF; Braunwald E; Redfield MM;
    JAMA; 2013 Dec; 310(23):2533-43. PubMed ID: 24247300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
    Kurien S; Warfield KT; Wood CM; Miller WL
    Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial.
    Triposkiadis FK; Butler J; Karayannis G; Starling RC; Filippatos G; Wolski K; Parissis J; Parisis C; Rovithis D; Koutrakis K; Skoularigis J; Antoniou CK; Chrysohoou C; Pitsavos C; Stefanadis C; Nastas J; Tsaknakis T; Mantziari L; Giannakoulas G; Karvounis H; Kalogeropoulos AP; Giamouzis G
    Int J Cardiol; 2014 Mar; 172(1):115-21. PubMed ID: 24485633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal effects of added low-dose dopamine in acute heart failure patients with diuretic resistance to natriuretic peptide.
    Kamiya M; Sato N; Nozaki A; Akiya M; Okazaki H; Takahashi Y; Mizuno K; Shimizu W
    J Cardiovasc Pharmacol; 2015 Mar; 65(3):282-8. PubMed ID: 25748698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure.
    Shah RV; McNulty S; O'Connor CM; Felker GM; Braunwald E; Givertz MM
    Am Heart J; 2012 Dec; 164(6):862-8. PubMed ID: 23194486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database.
    Costanzo MR; Johannes RS; Pine M; Gupta V; Saltzberg M; Hay J; Yancy CW; Fonarow GC
    Am Heart J; 2007 Aug; 154(2):267-77. PubMed ID: 17643575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ventriculoarterial coupling changes on renal function, echocardiographic indices and energy efficiency in patients with acute decompensated systolic heart failure under furosemide and dopamine treatment: a comparison of three therapeutic protocols.
    Antoniou CK; Chrysohoou C; Lerakis S; Manolakou P; Pitsavos C; Tsioufis K; Stefanadis C; Tousoulis D
    Int J Cardiol; 2015 Nov; 199():44-9. PubMed ID: 26186629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion of furosemide combined with low-dose dopamine compared to intermittent boluses in acutely decompensated heart failure is less nephrotoxic and carries a lower readmission at thirty days.
    Aziz EF; Alviar CL; Herzog E; Cordova JP; Bastawrose JH; Pamidimukala CK; Tojino A; Park TS; Musat D; Kukin M
    Hellenic J Cardiol; 2011; 52(3):227-35. PubMed ID: 21642071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow.
    Ezekowitz JA; Hernandez AF; O'Connor CM; Starling RC; Proulx G; Weiss MH; Bakal JA; Califf RM; McMurray JJ; Armstrong PW
    J Am Coll Cardiol; 2012 Apr; 59(16):1441-8. PubMed ID: 22497823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ROSE-AHF and lessons learned.
    Jain AK; Chen HH
    Curr Heart Fail Rep; 2014 Sep; 11(3):260-5. PubMed ID: 24966060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial.
    Giamouzis G; Butler J; Starling RC; Karayannis G; Nastas J; Parisis C; Rovithis D; Economou D; Savvatis K; Kirlidis T; Tsaknakis T; Skoularigis J; Westermann D; Tschöpe C; Triposkiadis F
    J Card Fail; 2010 Dec; 16(12):922-30. PubMed ID: 21111980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure.
    Cotter G; Weissgarten J; Metzkor E; Moshkovitz Y; Litinski I; Tavori U; Perry C; Zaidenstein R; Golik A
    Clin Pharmacol Ther; 1997 Aug; 62(2):187-93. PubMed ID: 9284855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial.
    Witteles RM; Kao D; Christopherson D; Matsuda K; Vagelos RH; Schreiber D; Fowler MB
    J Am Coll Cardiol; 2007 Nov; 50(19):1835-40. PubMed ID: 17980248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction.
    Riter HG; Redfield MM; Burnett JC; Chen HH
    J Am Coll Cardiol; 2006 Jun; 47(11):2334-5. PubMed ID: 16750705
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolic and toxicological considerations for diuretic therapy in patients with acute heart failure.
    Aspromonte N; Cruz DN; Valle R; Bonello M; Tubaro M; Gambaro G; Marchese G; Santini M; Ronco C
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1049-63. PubMed ID: 21599566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
    Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
    Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
    Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
    J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.